SCHEMBL23217213

SCHEMBL23217213

COc1ccc(Cl)c(Cl)c1CC(C)(O)[C@@H]1CCN(C(=O)O)C1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.36
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
S1PR1 P21453 1/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
PDE4B Q07343 1/20 0.34
RORC P51449 3/20 0.34
OPRD1 P41143 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
SPTLC2 O15270 2/20 0.34
NPY2R P49146 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28827789 0.80 MAPT (0.39) DRD2ALDH1A1LMNAMEN1KMT2A
SCHEMBL23217162 0.75 ALDH1A1 (0.38) DRD2ALDH1A1PKMS1PR1LMNA
SCHEMBL23217430 0.74 S1PR1 (0.38) DRD2ALDH1A1PKMS1PR1LMNA
SCHEMBL23216508 0.74 SMN1; SMN2 (0.45) ALDH1A1LMNAMEN1KMT2AAPOBEC3A
SCHEMBL28827794 0.68 ALDH1A1 (0.37) DRD2ALDH1A1PKMLMNAMEN1
SCHEMBL28827759 0.67 DRD2 (0.37) DRD2ALDH1A1PKMLMNAMEN1
SCHEMBL29782192 0.66 HPGD (0.45) LMNAMEN1KMT2APDE4BMAPT
SCHEMBL29745210 0.66 HPGD (0.45) LMNAMEN1KMT2APDE4BMAPT
SCHEMBL23217050 0.66 LMNA (0.37) DRD2ALDH1A1PKMLMNAMEN1
SCHEMBL572692 0.64 CYP2D6 (0.39) ALDH1A1LMNANPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-02-16 US disclosed
EP-4041405-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. Shaw Research, LLC (US) 2022-08-17 EP disclosed
CN-114828963-A Arylheterobicyclic compounds as Kv1.3 potassium SHAKER channel blockers D·E·萧尔研究有限责任公司 2022-07-29 CN disclosed
WO-2021071832-A1 ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D.E. SHAW RESEARCH, LLC (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230049231-A1 ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS KCNB1, KCNJ2, KCNB2 DRD2 1975/4885ALDH1A1 3120/4885PKM 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.